NEW YORK--(BUSINESS WIRE)--LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of CorMedix Inc. (“CorMedix”) (NYSE AMEX: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease.
